Researchers investigating how well the chemotherapy drug sunitinib works against various types of cancer have overestimated the drug’s effectiveness by an average of 45 percent, an analysis shows.
Valerie Henderson of McGill University in Montreal and colleagues reexamined data from 158 experiments involving 2,716 animals, mostly mice.
Log in
Subscribers, enter your e-mail address for full access to the Science News archives and digital editions.